Elizabeth A. Olek
Directeur Technique/Scientifique/R&D chez KRONOS BIO, INC.
Fortune : 189 410 $ au 30/04/2024
Profil
Elizabeth A.
Olek is currently working as the Senior Vice President-Clinical Development at Kronos Bio, Inc. She previously worked as the Director-Clinical Research at Genetics Institute LLC from 1998 to 2002, Director-Clinical Research at InterMune, Inc. from 2003 to 2004, Global Brand Medical Director at Novartis Pharmaceuticals Corp.
from 2005 to 2007, Director-Clinical Research at Wyeth Research from 1998 to 2002, Executive Director-Clinical Research at Loxo Oncology, Inc. from 2019 to 2022, and Chief Medical Officer & SVP-Clinical Development at Achillion Pharmaceuticals, Inc. from 2011 to 2012.
Dr. Olek holds a graduate degree from Boston University, an undergraduate degree from the University of the Sciences in Philadelphia, and a doctorate degree from the Philadelphia College of Osteopathic Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KRONOS BIO INC
0,32% | 21/02/2024 | 193 275 ( 0,32% ) | 189 410 $ | 30/04/2024 |
Postes actifs de Elizabeth A. Olek
| Sociétés | Poste | Début |
|---|---|---|
| KRONOS BIO, INC. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Elizabeth A. Olek
| Sociétés | Poste | Fin |
|---|---|---|
| LOXO ONCOLOGY INC | Corporate Officer/Principal | 01/02/2022 |
| ACHILLION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 18/06/2012 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/11/2007 |
| INTERMUNE INC | Directeur Technique/Scientifique/R&D | 01/07/2004 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/12/2002 |
Formation de Elizabeth A. Olek
| Boston University | Graduate Degree |
| University of the Sciences in Philadelphia | Undergraduate Degree |
| Philadelphia College of Osteopathic Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KRONOS BIO, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Wyeth Research
 Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The private company is based in Cambridge, MA. | Commercial Services |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
